Catalent Pharma Solutions has entered into a collaboration with Sanofi-Aventis R&D to implement Catalent’s SMARTag technology in the development of next generation Antibody-Drug Conjugates (ADCs). Catalent will develop site-specifically modified antibody conjugates using Sanofi’s antibodies, enabling Sanofi to evaluate site selective payload conjugation in order to enhance ADC pharmacokinetics, efficacy and safety.   The collaboration will involve teams at Sanofi and Catalent’s facility in E...